December 3, 2014
Since the late 1990s, new regulations have given us the opportunity to address the needs of the most vulnerable and demanding patients – children. Making medicines for pediatrics adds a whole new dimension to the challenges of formulation and drug delivery, but as our knowledge expands, exciting new developments are in the pipeline.
0 min read
December 2, 2014
A group of researchers have used supercomputers to link proteins to drug side effects (1). Could this computational model be more predictive than current statistical methods?
0 min read
December 2, 2014
Pathways designed to bring medicines to market faster in Europe are not delivering the goods
0 min read
December 2, 2014
Micreos, a biotech based in the Netherlands, has launched the first endolysin registered for human use against methicillin-resistant Staphylococcus aureus. What is an endolysin? Micreos describes it as a “bacteria-killing enzyme” that originates from bacteriophages. We spoke with Bjorn Herpers from the Regional Public Health Laboratory Kennemerland, Haarlem, in the Netherlands to find out more.
0 min read
December 2, 2014
Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).
0 min read
December 2, 2014
Science and business: tenacious partners in a shaky marriage or eternally bound nonidentical twins?
0 min read
December 2, 2014
Electrochemical reaction cells are finding new applications in the pharma R&D lab that could offer big time and cost savings. Here, we share our experiences using electrochemistry with on-line mass spectrometry to study pharmaceutical stability and oxidation products – and explain why we’re electrochemistry converts.
0 min read
December 2, 2014
Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated – especially when products share the same name.
0 min read
December 1, 2014
Upstream processes in biopharma manufacturing are growing ever more efficient; conversely, downstream processing is increasingly a bottleneck. Can a new generation of chromatography techniques and technologies get things moving again?
0 min read
